Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00586703 · ClinicalTrials.gov registry record · Phase 1
Safety Trial of NK Cell DLI 3-5/6 Family Member Following Nonmyeloablative ASCT
A Phase 1 study, sponsored by David Rizzieri, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT00586703 is a Phase 1 study that has completed, run by David Rizzieri, MD. The registered enrollment target is 21 participants.
The verdict
NCT00586703, a Phase 1 study, has completed, sponsored by David Rizzieri, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
Evaluate the safety of natural killer (NK) cell infusion using CD56 monoclonal antibody selected with Miltenyi Biotec system following nonmyeloablative stem cell transplantation (SCT) from mismatched donors. This pilot study will evaluate toxicity including mortality, occurrence of acute graft versus host disease (aGVHD) and other severe toxicity.
Interventions
- DEVICE NK-CD56
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2005-04 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00586703
The ClinicalTrials.gov registry entry for NCT00586703 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is David Rizzieri, MD, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NK-CD56 is the first listed.
NCT00586703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00586703 about?
NCT00586703 is a clinical study titled "Safety Trial of NK Cell DLI 3-5/6 Family Member Following Nonmyeloablative ASCT". Evaluate the safety of natural killer (NK) cell infusion using CD56 monoclonal antibody selected with Miltenyi Biotec system following nonmyeloablative stem cell transplantation (SCT) from mismatched donors. This pilot study will evaluate toxicity including mortality, occurrence of acute graft versu...
What is the current status of trial NCT00586703?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2005-04. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00586703?
The interventions under investigation include: NK-CD56 (DEVICE).
Who is sponsoring clinical trial NCT00586703?
This trial is sponsored by David Rizzieri, MD, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.